Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
The Globe and Mail - The Globe and Mail
US FDA approves Biogen-Sage Therapeutics pill for postpartum depression - Yahoo Lifestyle UK
Sage Therapeutics (NASDAQ:SAGE) Cut to Sell at StockNews.com - Defense World
Q1 2024 EPS Estimates for Sage Therapeutics, Inc. Decreased by Analyst (NASDAQ:SAGE) - Defense World
Sage Therapeutics (NASDAQ:SAGE) Given New $19.00 Price Target at Scotiabank - Defense World
Sage Therapeutics (NASDAQ:SAGE) Stock Rating Reaffirmed by Needham & Company LLC - Defense World
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $17.00 - Defense World
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $16.00 by Analysts at TD Cowen - Defense World
Sage Therapeutics stock plunges 20 percent after Parkinson's drug fails study - MSN
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success - MSN
Pages
1
2
3
4
5
6
7
8
9
next ›
last »
×